The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation

The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation

Background: There is no single definitive test to identify prostate cancer in men. Biopsies are commonly used to obtain samples of prostate tissue for histopathological examination. However, this approach frequently misses cases of cancer, meaning that repeat biopsies may be necessary to obtain a di...

Full description

Bibliographic Details
Main Authors: Amanda Nicholson, James Mahon, Angela Boland, Sophie Beale, Kerry Dwan, Nigel Fleeman, Juliet Hockenhull, Yenal Dundar
Format: Article
Language:English
Published: NIHR Journals Library 2015-10-01
Series:Health Technology Assessment
Subjects:
clinical effectiveness
cost-effectiveness
progensa pca3 assay
prostate health index
phi
diagnosis
prostate cancer
systematic review
economic evaluation
Online Access:https://doi.org/10.3310/hta19870

Similar Items

Similar Items